Ovarian Failure: IVF Evaluation and Considerations in China

Evaluate the feasibility, success rates, protocol options, and considerations for IVF in China for patients with Premature Ovarian Insufficiency (POI/POF). Based on core indicators such as AMH, FSH, and antral follicle count, analyze the applicable conditions and decision logic for pathways including mild stimulation, natural cycle, and egg donation.

Ovarian Failure: IVF Evaluation and Considerations in China
Special groups 2026-07-13

AI Summary

AI Summary The feasibility of IVF treatment for patients with Premature Ovarian Insufficiency in China depends on the degree of residual ovarian function, age, and concomitant diseases. AMH level, FSH level, and antral follicle count are core evaluation indicators. For patients with AMH ≥ 0.5 ng/mL and antral follicles ≥ 2, mild stimulation or natural cycle protocols can be used; for those with severe ovarian failure (undetectable AMH, persistent absence of antral follicles), egg donation is the primary alternative. Reproductive centers in China have accumulated extensive clinical experience in the field of Premature Ovarian Insufficiency, but a comprehensive fertility assessment, etiological screening, and genetic counseling must be completed before treatment. Treatment strategies vary significantly by age group; the cumulative live birth rate is relatively higher for patients aged ≤ 35 years with acceptable residual follicle function.
===== Main Content Begins =====

Patients with Premature Ovarian Insufficiency Undergoing IVF in China: Conditions and Boundaries

Whether patients with Premature Ovarian Insufficiency (medically termed Premature Ovarian Insufficiency, POI, and in some stages Premature Ovarian Failure, POF) are suitable for IVF treatment in China requires a comprehensive assessment based on specific ovarian reserve indicators, age, etiology, and previous treatment response. China has over 500 approved assisted reproductive institutions and has accumulated extensive clinical experience in managing poor ovarian response and POI. However, not all patients are suitable to directly enter a conventional controlled ovarian stimulation cycle.

Clinical Conditions Suitable for Autologous Egg IVF

  • AMH ≥ 0.5 ng/mL and Antral Follicle Count (AFC) ≥ 2 (confirmed by ultrasound on days 2-4 of menstruation)
  • Age ≤ 40 years, younger age correlates with relatively better egg quality and higher euploid embryo rate
  • Presence of intermittent or inducible follicular development, not a persistent state of no follicles
  • Normal uterine environment, no severe intrauterine adhesions, endometrial polyps, or fibroids affecting implantation
  • Both partners have normal karyotype, with no clear genetic cause leading to repeated failure

Cases Not Suitable for Direct Autologous Egg IVF

  • Undetectable AMH (< 0.01 ng/mL) and no antral follicles observed on ultrasound for 3 consecutive menstrual cycles
  • Age > 43 years with complete ovarian failure, autologous live birth rate below 5%
  • Comorbid uncontrolled autoimmune diseases (e.g., active thyroiditis, Addison's disease) or severe endocrine abnormalities
  • Confirmed genetic mutations related to Premature Ovarian Insufficiency (e.g., FMR1 premutation, FMN1) with multiple failed cycles yielding no usable embryos
  • Severe untreated uterine pathology (e.g., severe intrauterine adhesions, endometrial tuberculosis)

For patients unsuitable for autologous egg IVF, egg donation IVF or adoption are viable alternative paths. China has strict regulations for egg donation; donor sources are limited, waiting times are typically 1-3 years, and there are strict age and medical indication restrictions.

===== Physician Decision Pathway =====

Physician Decision Pathway: From Test Reports to Protocol Selection

In reproductive clinical practice, the management of patients with Premature Ovarian Insufficiency follows a stratified decision pathway, where each step relies on objective indicators rather than empirical guesswork.

Step 1: Confirm Diagnosis and Assess Residual Function

Core tests and their clinical significance:

Test Normal Reference Range Typical POI/POF Values Clinical Decision Significance
AMH 1.0-4.0 ng/mL < 0.5 ng/mL Indicates diminished reserve; < 0.1 ng/mL suggests extremely low reserve
FSH 3-10 IU/L > 25 IU/L (POI); > 40 IU/L (POF) Higher FSH indicates poorer ovarian response, necessitating mild stimulation or natural cycle
LH 2-9 IU/L Usually elevated alongside FSH LH/FSH ratio helps differentiate etiology
Antral Follicle Count (AFC) 5-20 (both ovaries) < 4 Directly reflects the number of recruitable follicles; 0 suggests difficulty with autologous eggs
Vitamin D > 30 ng/mL Often low in POI patients Vitamin D supplementation may improve follicular development and embryo quality

Step 2: Etiological Screening and Reversibility Assessment

  • Karyotype analysis: Rule out Turner syndrome, mosaicism, etc.
  • FMR1 gene testing: Rule out Fragile X premutation (associated with 2%-5% of POI)
  • Autoimmune antibody panel: Anti-ovarian antibodies, anti-adrenal antibodies, thyroid antibodies
  • Complete thyroid function: TSH, FT3, FT4, TPO antibodies, TG antibodies
  • Adrenal cortical function: ACTH, cortisol, rule out Addison's disease

Step 3: Develop Individualized Ovarian Stimulation Protocol

Ovarian Function Status Recommended Protocol Expected Oocyte Yield (per cycle) Notes
AMH 0.5-1.0 ng/mL, AFC 2-4 Mild Stimulation Protocol (Clomiphene + low-dose HMG) 1-3 Cumulative cycle strategy, frozen embryo transfer
AMH 0.1-0.5 ng/mL, AFC 1-2 Modified Natural Cycle / Natural Cycle Oocyte Retrieval 0-2 Requires close monitoring of LH surge, trigger if necessary
AMH < 0.1 ng/mL, AFC 0 Egg Donation IVF / Ovarian Activation (experimental) Very low success with autologous eggs Decision recommended after genetic counseling
===== Differences by Age Group =====

Differences in Treatment Strategies by Age Group

Age is a critical variable affecting IVF success rates in patients with Premature Ovarian Insufficiency, with an effect independent of AMH level. For the same AMH of 0.3 ng/mL, the euploid embryo rate and live birth rate differ significantly between a 25-year-old and a 42-year-old patient.

  • ≤ 35 years: Despite diminished ovarian reserve, egg quality is relatively better. After mild stimulation or natural cycle retrieval, the euploid embryo rate can reach 40%-60%. The cumulative live birth rate after 3-6 cycles can be 30%-50% (depending on the specific AMH level). Active attempts at autologous cycles are recommended.
  • 36-40 years: Both egg quantity and quality decline. More precise cycle monitoring is needed. It is recommended to attempt 3-6 consecutive mild stimulation or natural cycles, accumulate embryos, and then perform frozen embryo transfer. The live birth rate per cycle is about 8%-15%, with a cumulative live birth rate of about 20%-35%.
  • 41-43 years: Oocyte retrieval becomes significantly more difficult, and the euploid embryo rate drops to 15%-20%. After attempting 1-2 cycles, it is advisable to evaluate promptly whether to switch to egg donation based on embryo status.
  • > 43 years: The live birth rate with autologous IVF is very low (< 5%). Clinical guidelines generally recommend directly considering egg donation IVF to avoid ineffective expenditure of time and money.
===== Most Easily Overlooked Details =====

Most Easily Overlooked Tests and Preparation Details

In the treatment of patients with Premature Ovarian Insufficiency, the following items are often overlooked but have a direct impact on treatment outcomes:

  • Vitamin D Level: The incidence of vitamin D deficiency in POI patients is about 60%-80%. Supplementing to the normal range (> 30 ng/mL) may improve follicular development and embryo implantation.
  • Complete Thyroid Function + Antibodies: Autoimmune thyroid disease is highly comorbid with POI. Uncontrolled hypothyroidism or hyperthyroidism significantly reduces embryo implantation rates and increases miscarriage risk.
  • Adrenal Cortical Function Assessment: Rule out Addison's disease, especially when symptoms like fatigue, hypotension, skin hyperpigmentation, or anorexia are present.
  • Uterine Cavity Evaluation: Even with poor ovarian function, uterine pathologies (polyps, adhesions, endometritis) further reduce implantation rates. Routine hysteroscopy before transfer is recommended.
  • Partner Semen Analysis: Male factors can be additive, further reducing overall success rates. Do not assume the male partner has no issues.
===== Common Misconceptions =====

Common Cognitive Misconceptions and Pitfalls

Myth 1: Premature Ovarian Insufficiency = Complete Inability to Conceive

In reality, about 5%-10% of POI patients can achieve natural pregnancy, especially those with Premature Ovarian Insufficiency (POI) rather than complete failure (POF). Through mild stimulation or natural cycle IVF, some patients can still achieve pregnancy. Do not give up on the chance of using your own eggs without attempting.

Myth 2: High FSH Means IVF is Impossible

Elevated FSH reflects diminished ovarian reserve but does not mean a complete absence of eggs. Some patients with intermittently high FSH can still recruit follicles in cycles where FSH is relatively lower. Clinically, FSH < 15 IU/L is often used as a reference window for attempting mild stimulation.

Myth 3: Increasing Gonadotropin Dose Will Yield More Eggs

For patients with Premature Ovarian Insufficiency, increasing the dose of stimulation medication does not effectively increase the number of eggs retrieved and may instead increase side effects and costs. Mild stimulation and natural cycles are more reasonable choices; the core logic is "opportunistic retrieval" rather than "forced maturation."

Pitfall: Neglecting Luteal Phase Support

The incidence of luteal phase deficiency in natural cycles is extremely high in patients with Premature Ovarian Insufficiency. Adequate luteal phase support (progesterone) is needed after oocyte retrieval; otherwise, even with successful fertilization and transfer, implantation rates will drop significantly. It is recommended to start progesterone from the day of oocyte retrieval and continue until 10-12 weeks after transfer.

Clinical Recommendation: For patients with AMH ≤ 0.5 ng/mL, ovarian status (FSH, LH, E2, AFC) should be reassessed before each cycle. Do not simply repeat the previous protocol. Ovarian status fluctuates; seizing a good cycle window is more important than blindly starting a cycle.
===== Key Indicator Interpretation =====

In-Depth Interpretation of Key Diagnostic Indicators

For patients with Premature Ovarian Insufficiency, the interpretation of the following indicators needs to be combined with the clinical context:

Indicator Threshold Clinical Interpretation & Action Recommendations
AMH 0.5 ng/mL Below this value indicates severely diminished reserve; between 0.1-0.5 ng/mL, mild stimulation can still be attempted; undetectable suggests egg donation consultation
FSH 25 IU/L > 25 IU/L indicates ovarian insufficiency; > 40 IU/L indicates failure; but FSH fluctuates, requiring 2-3 consecutive measurements
Antral Follicle Count 2 ≥ 2 allows attempting autologous eggs; 1 allows attempting natural cycle; 0 for 3 consecutive months suggests egg donation
Vitamin D 30 ng/mL Generally low in POI patients; supplementing to the normal range may improve egg quality and embryo implantation rate
TSH 2.5 mIU/L For those planning pregnancy, it is recommended to keep TSH below 2.5; > 4.0 requires medical intervention
===== Practitioner Observations =====

Practitioner Observations: Current Status of Assisted Reproduction in China

As reproductive medicine practitioners, we observe the following trends and realities:

  • China's assisted reproductive technology has aligned with international standards in managing poor ovarian response. The application of mild stimulation protocols, natural cycle protocols, and follicular wave theory is now common. Compared to Europe and America, China's advantages lie in high cycle volume, rapid accumulation of clinical experience, and mature laboratory embryo culture techniques. Blastocyst culture rates and PGT technology in some centers have reached advanced international levels.
  • Experience and equipment vary among different reproductive centers. When choosing, pay attention to the center's experience in managing poor ovarian response cases and whether it has a dedicated POI/POF diagnosis and treatment pathway. It is recommended to choose centers with an annual cycle volume > 5,000 and a specialized reproductive immunology or ovarian function clinic.
  • Regarding egg donation, China has strict regulations. Donor eggs are limited to donations from concurrent IVF patients, sources are limited, and waiting times are typically 1-3 years. Egg donation IVF has strict age limits (generally ≤ 52 years) and medical indication requirements.
  • Ovarian activation techniques (such as ovarian cortical activation, stem cell therapy) remain at the experimental research stage and are currently not recommended as routine treatment. Related studies conducted in some centers require ethical review, and expected outcomes involve significant uncertainty.
===== Frequently Asked Questions =====

Summary of Frequently Asked Questions

Q: How long does it take to prepare for IVF with Premature Ovarian Insufficiency?

A: From the initial visit to completing one full cycle typically takes 2-3 months. This includes a 1-month evaluation period (chromosome, genetic, immune, endocrine tests, etc.) and 1-2 cycles of stimulation and transfer. If a cumulative embryo strategy (embryo banking) is used, it may take 6-12 months. It is advisable to allow sufficient time and not rush into a cycle.

Q: How low does AMH need to be before I cannot use my own eggs?

A: Clinically, an AMH < 0.01 ng/mL (undetectable) combined with no antral follicles observed on ultrasound for 3 consecutive menstrual cycles is often used as a stopping criterion for autologous IVF. However, if the patient is ≤ 35 years old and follicles appear intermittently, natural cycle retrieval can still be attempted, though the expected number of eggs is very low, requiring adjusted expectations.

Q: What is the approximate cost of IVF for Premature Ovarian Insufficiency?

A: In China, the cost for one mild stimulation or natural cycle IVF is approximately 20,000-40,000 RMB (including medication, monitoring, retrieval, embryo culture, and transfer fees). The cost for egg donation IVF is approximately 80,000-150,000 RMB (including donor compensation, embryo culture, and transfer fees). Specific costs vary by region, center, and individual protocol. A cumulative cycle strategy will significantly increase the total cost.

Q: Do patients with Premature Ovarian Insufficiency need genetic counseling?

A: Genetic counseling is recommended for all patients diagnosed with POI. About 10%-15% of POI cases are related to genetic factors, including FMR1 premutation, X chromosome abnormalities, and autosomal gene mutations (e.g., FSHR, BMP15). Identifying the genetic cause not only helps assess the genetic risk for offspring but also guides treatment strategy selection.

Q: Which is better, natural cycle or mild stimulation protocol?

A: There is no absolute better option; it depends on ovarian status. For patients with AMH < 0.3 ng/mL and AFC ≤ 2, a natural cycle or modified natural cycle is more suitable, reducing medication interference. For patients with AMH 0.3-0.8 ng/mL and AFC 2-4, a mild stimulation protocol can increase the number of eggs retrieved. The core principle of both protocols is "low dose, low intervention, cumulative strategy."

===== Conclusion =====
Risk Reminder: Before undergoing IVF treatment, patients with Premature Ovarian Insufficiency should fully understand the risks of poor ovarian response, cycle cancellation, no usable embryos, and higher miscarriage rates. It is recommended to choose a正规 reproductive center with reproductive genetic counseling capabilities and to complete a comprehensive fertility assessment and etiological screening before treatment. Maintain reasonable psychological expectations during treatment to avoid excessive medical intervention and financial burden due to multiple cycle failures.

This article is written based on consensus in assisted reproductive medicine and clinical practice, aiming to provide objective medical knowledge for reference and does not constitute treatment plan advice. For specific diagnosis and treatment, please consult a qualified reproductive medicine center.

Comments (0)

Leave a Comment